Profiling Insulin Oligomeric States by 1H NMR Spectroscopy for Formulation Development of Ultra-Rapid-Acting Insulin

J Pharm Sci. 2020 Jan;109(1):922-926. doi: 10.1016/j.xphs.2019.07.025. Epub 2019 Aug 23.

Abstract

Formulations that can increase the dissociation of insulin oligomers into monomers/dimers are important considerations in the development of ultra-rapid-acting insulins with faster onset and shorter duration of actions. Here we present a novel strategy to characterize the oligomeric states of insulin in solution that leverages the ability of nuclear magnetic resonance spectroscopy to assess higher-order structure of proteins in solution. The oligomeric structures and solution behaviors of 2 fast-acting insulins, aspart and lispro, with varying excipient concentrations were studied using 1D and diffusion profiling methods. These methods can provide insight on the structural differences and distributions of the molecular association states in different insulin formulations, which is consistent with other orthogonal biophysical characterization tools. In addition, these methods also highlight their sensitivity to subtle changes in solution behaviors in response to excipient that are difficult to monitor with other tools. This work introduces the utility of 1D and diffusion profiling methods to characterize the oligomeric assembly of fast-acting insulins, suggesting promising applications in compound screening, excipient selection, and formulation development of fast-acting insulins as well as other peptide or protein therapeutics.

Keywords: NMR spectroscopy; biopharmaceutical characterization; biosimilar; diffusion; drug-excipient interactions; excipients; insulin; protein formulation; self-association.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diffusion
  • Drug Compounding
  • Excipients / chemistry*
  • Insulin Aspart / chemistry*
  • Insulin Lispro / chemistry*
  • Protein Conformation
  • Proton Magnetic Resonance Spectroscopy*
  • Solubility

Substances

  • Excipients
  • Insulin Lispro
  • Insulin Aspart